Clinical Trial Update: SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease

View source ↗

Summary

The SEDPARK1 trial assessed the safety and efficacy of piribedil, a non-ergot dopamine agonist, in Parkinson's disease and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Piribedil (piribedil)

Snippet

Sponsor: Desitin Arzneimittel GmbH | Conditions: Parkinson's Disease | Status: COMPLETED